ReviewDrugs2014
Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02898012 (Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status), which is not on this map. Cited by 101 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)
Who cites it
101 citing papers in PubMed, 3 syntheses or guidelines pooled it, 225 citations in OpenAlex.
- Cross-sectional relation of long-term glucocorticoids in hair with anthropometric measurements and their possible determinants: A systematic review and meta-analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022Pooled it
- Coronary Heart Disease and Cardiovascular Risk Factors in Patients With Idiopathic Inflammatory Myopathies: A Systemic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls.Biological psychiatry · 2020Pooled it
- Efficacy of leflunomide in active Takayasu arteritis: a randomized double-blind placebo-controlled trial : Takayasu arteritis clinical trial in China (TACTIC).BMC medicine · 2026Trial
- Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.Blood advances · 2023Trial
- Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).The oncologist · 2018Trial
- Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.Advances in therapy · 2017Trial
- Emotional and Uncontrolled Eating as Mediators Between Perceived Stress and Adiposity Indicators in University Students: A Cross-Sectional Study.Brain and behavior · 2026Article
- Longitudinal alterations in lower extremity quantitative MRI metrics under simulated microgravity and their associations with systemic biomarkers.NPJ microgravity · 2026Article
- A Drug-Environment Interaction Between PMPharmacoepidemiology and drug safety · 2026Article
- Does cortisol mediate the association between school bullying and weight status in preadolescents?European child & adolescent psychiatry · 2026Article
- Article
- Burden of incident cardiovascular events in giant cell arteritis using data from a nationwide French cohort.Scientific reports · 2026Article
- Major adverse cardiovascular events in Sjögren's disease: incidence, associated factors, and impact on mortality in a prospective multicenter cohort.Rheumatology international · 2026Article
- Differential effects of GVHD therapies on intestinal epithelium.Blood advances · 2026Article
- Metabolic Disorders and Inflammatory Bowel Diseases: Unraveling Shared Pathways and Clinical Interactions.Metabolites · 2026Review
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
- Childhood systemic glucocorticoid exposure and subsequent alterations in myocardial structure and cardiac function: a narrative review of clinical evidence.Frontiers in endocrinology · 2026Review
- Obesity and Depression.Advances in experimental medicine and biology · 2026Review
- Obesity and Depression: A Pathophysiotoxic Relationship.International journal of molecular sciences · 2025Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of use of long-term systemic glucocorticoid therapy in the general adult population is 1 %. This figure increases to up to 3 % in elderly women. Metabolic (i.e. diabetes mellitus, dyslipidemia, weight gain, lipodystrophy) and cardiovascular (i.e. hypertension, cardiovascular events) adverse events are commonly observed in these patients and can be life threatening. Paradoxically, there is very few data on some of these adverse events and many of the available studies remain inconclusive. Incidence of and risk factors for dyslipidemia, weight gain and lipodystrophy are poorly defined. The optimal treatment plan for patients diagnosed with glucocorticoid-induced diabetes or hypertension is undetermined. Finally, there is no medical consensus on the best strategies for the prevention and detection of these complications. However, certain of these questions can be answered by looking at available data on patients with endogenous hypercortisolism (i.e. Cushing's syndrome). This article reviews the pathophysiology, incidence, risk factors, screening, and treatment of glucocorticoid-induced weight gain, lipodystrophy, diabetes, dyslipidemia, hypertension, and cardiovascular events. It also focuses on the possible prevention of these adverse events by targeting the glucocorticoid receptor using selective glucocorticoid receptor modulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.